RE:RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...JKJ, no offense but IMO the ASSURE failure was one of design not execution...IMO RVX failed to do sufficient pre-trial work to know the chance for lipitor-208 failure...PS i recently read an admission by a CEO of a CDN baby bio that the trial design was impacted by lack of funds (not RVX but this IMO is a huge risk in CDN babybio "do it in the cheap" which often turns out to be very expensive (I dumped a PIII CDN baby bio who went to Eastern Europe for patients (cheaper CRO costs) and the trial failed, recently the CEO admitted to "differing Standards of Care in different countries causing "placebo effect" or that the control group didn't act as expected)..